Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21 Journal Article


Authors: Gilewski, T.; Adluri, S.; Ragupathi, G.; Zhang, S.; Yao, T. J.; Panageas, K.; Moynahan, M.; Houghton, A.; Norton, L.; Livingston, P. O.
Article Title: Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21
Abstract: Our objective was to determine whether an immune response can be generated against MUC1 peptide and against tumor cell MUC1 after vaccination with MUC1-keyhole limpet hemocyanin (KLH) conjugate plus QS-21 in breast cancer patients. Nine patients with a history of breast cancer but without evidence of disease were treated with MUC1-KLH conjugate plus QS-21, containing 100 μg of MUC1 and 100 μg of QS-21. s.c. vaccinations were administered at weeks 1, 2, 3, 7, and 19. Peripheral blood was drawn at frequent intervals to assess antibody titers. Skin tests were placed at weeks 1, 3, 9, and 21 to determine delayed type hypersensitivity reactions. Common toxicities included a local skin reaction at the site of the vaccine, usually of 4-5 days' duration, and mild flu-like symptoms usually of 1-2 days' duration. High IgM and IgG antibody titers against synthetic MUC1 were detected. IgG antibody titers remain elevated from a minimum of 106-137 weeks after the first vaccination. Binding of IgM antibody to MCF-7 tumor cells was observed in seven patients, although there was minimal binding of IgG antibody. Two patients developed significant antibody titers post-high-dose chemotherapy and stem cell reinfusion. There was no evidence of T cell activation. This MUC1-KLH conjugate plus QS-21 was immunogenic and well tolerated in breast cancer patients. Additional trials are ongoing to determine the optimal MUC1 peptide for use in larger clinical trials. Further investigation of vaccine therapy in high-risk breast cancer is warranted.
Keywords: adult; clinical article; treatment outcome; middle aged; drug tolerability; fatigue; diarrhea; neoplasm staging; breast cancer; bone marrow suppression; nausea; tumor cells, cultured; breast neoplasms; high risk patient; time factors; fever; skin; amino acid sequence; molecular sequence data; immunoglobulin g; cancer vaccines; antibody response; peptide fragments; vaccination; flu like syndrome; headache; antibodies; adjuvants, immunologic; cell strain mcf 7; drug induced disease; antibody titer; keyhole limpet hemocyanin; hemocyanin; immunoglobulin m; hematologic diseases; mucin; qs 21; ca-15-3 antigen; humans; human; female; priority journal; article
Journal Title: Clinical Cancer Research
Volume: 6
Issue: 5
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2000-05-01
Start Page: 1693
End Page: 1701
Language: English
PUBMED: 10815887
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus